Geron (GERN)
(Delayed Data from NSDQ)
$3.79 USD
+0.23 (6.46%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.79 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
GERN 3.79 +0.23(6.46%)
Will GERN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for GERN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GERN
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
Company News for Mar 18, 2024
GERN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up
Implied Volatility Surging for Geron (GERN) Stock Options
Geron (GERN) Upgraded to Buy: Here's Why
Other News for GERN
Skechers Reports Upbeat Earnings, Joins Tutor Perini, AppFolio, Newell Brands And Other Big Stocks Moving Higher On Friday
Interesting GERN Put And Call Options For June 7th
Geron to Announce First Quarter 2024 Financial Results on May 2, 2024
3 Red-Hot Biotech Rockets Blasting Off in 2024
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)